This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Rotavirus vaccine, human rotavirus
Rotarix is an oral, two-dose, live attenuated vaccine developed from a single human strain designed to provide broad protection against multiple rotavirus strains. The vaccine works by stimulating the body to mimic the immune response to natural rotavirus infection, the leading cause of severe diarrhea and vomiting in infants and young children between 3-24 months world-wide.
As a two dose vaccine, Rotarix has an advantage over Merck's competing RotaTeq vaccine, which requires 3 doses. Sales of Rotarix, however, have been hindered by studies suggesting a moderately increased risk of intussusception.
Deal Structure: In February 2006, Rotarix was approved in Europe, triggering a $4 million milestone payment from GSK to AVANT.
In July 2011, GlaxoSmithKline and Daiichi Sankyo reached an agreement for the co-promotion in Japan of Rotarix.
Partners: Celldex Therapeutics, Inc.
Additional information available to subscribers only: